A multicenter, randomized controlled study on the efficacy of agomelatine in ameliorating anhedonia, reduced motivation, and circadian rhythm disruptions in patients with major depressive disorder (MDD)

Table 3 Comparison of remission rates between the two groups after 12 weeks of treatment (n, %)

Group	N	Baseline	End of Week 2	End of Week 4	End of Week 8	End of Week 12
Agomelatine Group	90	0	18 (20.0)	31 (34.4)	45 (50.0)	57 (63.3)
SSRIs Group	90	0	12 (13.3)	32 (35.6)	52 (57.8)	65 (72.2)
			χ² = 1.440 P = 0.230	χ² = 0.024 P = 0.876	χ² = 1.096 P = 0.295	χ² = 1.628 P = 0.202

SSRIs denote Selective Serotonin Reuptake Inhibitors. After adjusting for the effects of different centers, a chi-square test was used to compare the differences in remission rates between the two groups at each visit point, all suggesting P > 0.05

ISSN: 1744-859X